Abstract
Background [18F]FDG Positron Emission Tomography cannot differentiate between sterile inflammation and infection. Therefore, we, aimed to develop more specific radiotracers fitted for differentiation between sterile and septic infection to improve the diagnostic accuracy. Consequently, the clinicians can refine the treatment of, for example, prosthesis-related infection. Methods: We examined different target points; Staphylococcus aureus biofilm (68Ga-labeled DOTA-K-A9 and DOTA-GSGK-A11), bone remodeling ([18F]NaF), bacterial cell membranes ([68Ga]Ga-Ubiquicidin), and leukocyte trafficking ([68Ga]Ga-DOTA-Siglec-9). We compared them to the well-known glucose metabolism marker [18F]FDG, in a well-established juvenile S. aureus induced osteomyelitis (OM) pig model. Results: [18F]FDG accumulated in the OM lesions seven days after bacterial inoculation, but disappointingly we were not able to identify any tracer accumulation in OM with any of the supposedly more specific tracers. Conclusion: These negative results are, however, relevant to report as they may save other research groups from conducting the same animal experiments and provide a platform for developing and evaluating other new potential tracers or protocol instead.
Highlights
Staphylococcus aureus (S. aureus) causes skin, soft tissue, bone, pleuropulmonary infections, infective endocarditis, sepsis, osteoarticular, and device-related infections [1]
The prevalence of specific Multi-Drug Resistant (MDR) bacteria is associated with the usage of broad-spectrum antibiotics, both for empiric as well as for definite therapy [4]
2.8 million antibiotic-resistant infections occur in the U.S each year, and more than 35,000 people die as a result [5]
Summary
Staphylococcus aureus (S. aureus) causes skin, soft tissue, bone, pleuropulmonary infections, infective endocarditis, sepsis, osteoarticular, and device-related infections [1]. To prevent disease progression and to reduce the number of complications, it is essential to diagnose bacterial infections at an early stage and initiate the best therapy. As stated by the WHO and others, the annual consumption of antibiotics is increasing, and the support for its use is often insignificant [2,3]. The prevalence of specific Multi-Drug Resistant (MDR) bacteria is associated with the usage of broad-spectrum antibiotics, both for empiric as well as for definite therapy [4]. 2.8 million antibiotic-resistant infections occur in the U.S each year, and more than 35,000 people die as a result [5]. To use the correct treatment, clinicians need to identify the location of inflammation
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
